cAd3-Marburg vaccine

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Albert B. Sabin Vaccine Institute

Conditions

Marburg Virus Disease

Phase 1

cAd3-Marburg Vaccine in Healthy Adults

CompletedNCT03475056

National Institute of Allergy and Infectious Diseases (NIAID)Marburg Virus Disease

Start: 2018-10-09End: 2019-12-19Updated: 2022-08-11

Phase 2

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

CompletedNCT05817422

Albert B. Sabin Vaccine InstituteMarburg Virus Disease

Start: 2023-10-19End: 2025-04-25Updated: 2025-07-23

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Active, not recruitingNCT06620003

Albert B. Sabin Vaccine InstituteMarburg Virus Disease

Start: 2025-04-14End: 2026-10-01Target: 200Updated: 2026-09-10

Related Papers

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.

2023-01-0149 citations